Selinexor is a highly selective XPO1 inhibitor which has been FDA approved for the treatment of refractory multiple myeloma and diffuse large B-cell lymphoma, and is being currently evaluated in clinical trials for other cancers (for example, currently in Phase 3 or 4: NCT05028348, NCT05611931, NCT04562389, NCT05726110). Here, XPO1 is linked to cancer.